Repatha works by blocking a specific enzyme in your liver to help your body remove cholesterol more effectively. It is not an immunosuppressant drug, so it doesn’t work by suppressing the immune ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug Repatha (evolocumab). In August 2025, the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results